We source and manage opportunistic investments.

We exploit dislocations in markets and unlock value from complex situations using a Create Capital and Preserve Capital strategy. This strategy has given rise to returns over 23 years of 28% p.a. Net IRR

Atlantic SuperConnection — Our portfolio includes Atlantic SuperConnection

Atlantic SuperConnection (ASC) is developing a c1,500km subsea High Voltage Direct Current (HVDC) cable to bring 1GW of baseload and on-demand geothermal and hydro-electrical power from Iceland to the UK.
See How

Brooklyn ImmunoTherapeutics — Our portfolio includes Brooklyn ImmunoTherapeutics

Brooklyn ImmunoTherapeutics is a clinical-stage bioresearch company developing IRX-2, an important new immunotherapy candidate for cancer.
See How

REG (Regulatory Efficiency Gains) — Our portfolio includes REG (Regulatory Efficiency Gains)

REG aims to become the go-to solution for Insurance Intermediaries looking to Streamline Broker/Agency Compliance and Management Processes.
See How

Pension Insurance Corporation — Our portfolio includes Pension Insurance Corporation

Pension Insurance Corporation provides tailored pension insurance buyouts and buy-ins, or bulk annuities, to the trustees and sponsors of UK defined pension funds.
See How

Tungsten — Our portfolio includes Tungsten

Tungsten Corporation is a leading global supply chain enabler headquartered in the heart of London. It is a team of technologists, B2B commerce experts, process mavens, and digital evangelists dedicated to accelerating global trade...
See How

Ptarmigan Health Destinations — Our portfolio includes Ptarmigan Health Destinations

Ptarmigan is developing Val d’Hérens (Swiss Canton of Valais) into a sustainable world-class Alpine health destination.
See How

Pension Insurance Corporation

Atlantic SuperConnection

REG (Regulatory Efficiency Gains)

Meet the team

Edi Truell

Edi Truell

Director

Cédriane de Boucaud

Cédriane de Boucaud

Director

Roger Le Tissier

Roger Le Tissier

Director

News from Disruptive Capital GP Limited

Supporting the next career step for service leavers

Supporting the next career step for service leavers

As Armed Forces Day on 26th June fast-approaches, Telent remains committed to helping service leavers transition successfully out of the forces and thrive in the next chapter of their lives.

Telent secure additional contract from Openreach for Full Fibre build programme

Telent secure additional contract from Openreach for Full Fibre build programme

Telent Infrastructure Services (TIS) has been successful in winning a further 106 Fibre-to-the-Premises (FTTP) build locations amounting to almost 950,000 premises which will receive ultra-fast broadband as part of the latest wave of Openreach tenders. This builds on the 53, Falcon 1a exchanges, locations awarded in August 2020.

Tungsten appoints new CEO

Tungsten appoints new CEO

The board of Tungsten Network announces that Andrew Lemonofides, Chief Executive Officer, having overseen the recent transformation of the Company, will be leaving Tungsten at the end of June and will step down from the board with immediate effect.

Tungsten Network launches cloud-based Universal Workflow product

Tungsten Network launches cloud-based Universal Workflow product

Tungsten Network today announces the launch of Universal Workflow, a cloud-based solution that provides customers the flexibility to connect to any and multiple ERP systems.

6 ways Regtech can transform your business

6 ways Regtech can transform your business

The benefits of Regtech adoption to enhance regulatory processes and streamline due diligence are profound. However, the advantages of the software are not just central to improvements in your governance and oversight. Businesses as a whole have noted improvements on a holistic scale.

Brooklyn ImmunoTherapeutics Executes Letter of Intent to Buy Novellus Therapeutics

Brooklyn ImmunoTherapeutics Executes Letter of Intent to Buy Novellus Therapeutics

Brooklyn ImmunoTherapeutics said Monday it has executed a letter of intent to buy Novellus Therapeutics, a company developing mesenchymal stem cell therapies.

More News